Medtech Portfolio Optimization: Why Investors Say No

In the medtech world, a “no” from an investor isn’t always what it seems. The decision to pass on a startup often comes down to more than just the technology—it’s a balancing act of risk, timing, and fit. And for the investors themselves, building a smart portfolio means getting comfortable with saying no—a lot.

That’s what the panelists unpacked during Investors That Pass—a candid conversation on how venture capitalists make the tough calls regarding medtech portfolio optimization. Drawing from their personal experience, the panelists pulled back the curtain on why even the most promising companies don’t always get a “yes.”

Originally published at: https://www.lsieuropesummit.com/news/medtech-portfolio-optimization-why-investors-say-no-and-what-that-really-means


Comments

Popular posts from this blog

Consumerization of Healthcare: Understanding Patient Behavior

The Global Stage for Live-Saving Innovation